References
- Barza M, Lauermann M. Why monitor serum levels of gentamicin?. Clin Pharmacokinet 1978; 3: 202–215
- Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986; 80: 98–104, Suppl. 6B
- Noone P, Parsons T MC, Pattison JR, Slack R CB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; 1: 477–481
- Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteriemia. J Infect Dis 1984; 149: 443–448
- Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–99
- Maller R, Isaksson B, Nilsson L, Sörén L. Aminoglycoside therapy once daily in serious systemic infections. J Antimicrob Chemother 1988; 22: 75–79
- Nilsson L. Rapid bioluminescent assay of serum amikacin. J Antimicrob Chemother 1982; 10: 125–130
- Metzler CM, Elfring GI, McEwen AJ. A package of computer programs for pharmacokinetic modelling. Biometrics 1974; 30: 562–563
- Nordström L, Cronberg S, Ringberg H, Tjernström O, Walder M. Prospective comparative, randomized clinical study of aminoglycosides given once a day versus three times a day in severe infections. Recent advances in chemotherapy, J Ishigami. University of Tokyo Press, Tokyo 1985; 2653–2654
- Pechere J-C, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clin Pharmacokinet 1979; 4: 170–199
- Pijck J, Hallynck T, Soep H, Baert L, Daneels R, Boelaert J. Pharmacokinetics of amikacin in patients with renal insufficiency: Relation of half-life and creatinine clearance. J Infect Dis 1976; 134: 331–341, Suppl
- Clarke JT, Libke RD, Regamy C, Kirby W MM. Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther 1974; 15: 610–616
- Lanao JM, Dominguez-Gil A, Dominguez-Gil AA, Malaga S, Crespo M, Nuno F. Modification in the pharmacokinetics of amikacin during development. Eur J Clin Pharmacol 1982; 23: 155–160
- Kahlmeter G, Jonsson S, Kamme C. Longstanding post-therapeutic gentamicin serum and urine concentrations in patients with unimpaired renal function. A pharmacokinetic evaluation. J Antimicrob Chemother 1978b; 4: 143–152
- Kahlmeter G, Jonsson S, Kamme C. Multiple-compartment pharmacokinetics of tobramycin. J Antimicrob Chemother 1978; 4: 5–11, Suppl A
- Luft FC, Patel V, Moo NY, Patel B, Kleit SA. Experimental aminoglycoside nephrotoxicity. J Lab Clin Med 1975; 86: 213–220
- De Broe ME, Verpooter GA, Giuliano R, Paulus GJ, Tulkens PM, Roels F. Early toxicity of aminoglycosides in human kidney: A prospective, comparative study of amikacin, gentamicin, netilmicin and tobramycin. Chemotherapia 1984; 3: 72–79, Suppl
- McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL. Pharmacokinetics of amikacin in patients with impaired renal function. J Infect Dis 1976; 134: 343–348, Suppl
- Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE. Pharmacokinetics of amikacin in patients with normal or impaired renal function: Radioenzymatic acetylation assay. J Infect Dis 1976; 134: 323–330, Suppl